Newborn screening is a public health program provided by most of the countries around the world aimed at screening newborns for a list of serious genetic and metabolic disorders . Early diagnosis of those conditions can help prevent their further development which untreated often results in brain damage, organ damage and even death.
Nowadays, a routine neonatal screening procedure requires that a health professional takes a few drops of blood from the baby’s heel, applies them onto filter paper and sends such prepared samples to a laboratory for a number of analytical tests. Current sample preparation taking place before analysis may be labor-intensive, time-consuming and not very precise due to carry-over when processed with traditional “punch-and-elute” methodology. Most laboratories still perform the MS analysis from one DBS disc and the biological assays from a second disc. Application of DBS-MS 500 will standardize the sample preparation and analytical process, while also simplifying the workflow and eliminating any manual working steps.
 B. L. Therrell, C. D. Padilla, J. G. Loeber, I. Kneisser, A. Saadallah, G. J. C. Borrajo, and J. Adams, “Current status of newborn screening worldwide: 2015,” Semin. Perinatol., vol. 39, no. 3, pp. 171–187, 2015.